Europese Unie - Nederlands - EMA (European Medicines Agency)

bavarian nordic a/s - modified vaccinia ankara - beierse nordic (mva-bn) -virus - smallpox vaccine; monkeypox virus - andere virale vaccins, - active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4. 4 en 5. het gebruik van dit vaccin moet gebeuren in overeenstemming met officiële aanbevelingen.

Europese Unie - Nederlands - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - hemorragische koorts, ebola - vaccins - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bavarian nordic a.s. - levend, geattenueerd, salmonella typhi 2 10*9 cfu/dosis - maagsapresistente capsule, hard - salmonella typhi - typhoid, oral, live attenuated

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

bavarian nordic a/s philip heymans allé 3 2900 hellerup (denemarken) - rabiËsvirusantigeen, flury lep, geinactiveerd 2,5 >= ie/flacon - poeder en oplosmiddel voor oplossing voor injectie - dinatriumedetaat 2-water ; kaliumwaterstofglutamaat (l-vorm) (e 622) ; natriumchloride ; polygeline ; saccharose ; trometamol ; water voor injectie, - rabies, inactivated, whole virus

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bavarian nordic a.s. - geïnactiveerd rabiësvirus >= 2,5 ie - poeder en oplosmiddel voor oplossing voor injectie in een voorgevulde spuit - geïnactiveerd rabiësvirus - rabies, inactivated, whole virus

Europese Unie - Nederlands - EMA (European Medicines Agency)

bavarian nordic a/s - vibrio cholerae, stam cvd-103-hgr, live - cholera - vaccins - vaxchora is indicated for active immunisation against disease caused by vibrio cholerae serogroup o1 in adults and children aged 2 years and older. dit vaccin moet worden gebruikt in overeenstemming met de officiële aanbevelingen.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

emergent netherlands b.v. strawinskylaan 411 1077 xx amsterdam - levend verzwakt salmonella enterica serovar typhi, stam ty21a 2000000000 > cfu/stuk - maagsapresistente capsule, hard - ascorbinezuur (l-) (e 300) ; caseÏne hydrolysaat ; diethylftalaat ; erythrosine (e 127) ; ethyleenglycol ; gelatine (e 441) ; hypromelloseftalaat ; ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; lactose 0-water ; magnesiumstearaat (e 470b) ; saccharose ; titaandioxide (e 171) - typhoid, oral, live attenuated

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

medcor pharmaceuticals b.v. artemisweg 232 8239 de lelystad - rabiËsvirusantigeen, flury lep, geinactiveerd - poeder en oplosmiddel voor oplossing voor injectie - dinatriumedetaat 2-water ; kaliumwaterstofglutamaat (l-vorm) (e 622) ; natriumchloride ; polygeline ; saccharose ; trometamol ; water voor injectie, - rabies, inactivated, whole virus

Europese Unie - Nederlands - EMA (European Medicines Agency)

dynavax gmbh - hepatitis b-oppervlakte-antigeen - hepatitis b - vaccins - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

Europese Unie - Nederlands - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.